IL1B and breast cancer: In contrast to the increased risk of the IL1-RN polymorphism for cancers, a decreased risk was also observed in breast cancer (2L versus LL: OR = 0.74, 95% CI: 0.58–0.93, Pheterogeneity = 0.844; 2L+22 versus LL: OR = 0.78, 95% CI: 0.62–0.97, Pheterogeneity = 0.632).